ATE425750T1 - Verwendung von triglyceriden mit mittellangen ketten zur behandlung und vorbeugung der alzheimerschen erkrankung - Google Patents
Verwendung von triglyceriden mit mittellangen ketten zur behandlung und vorbeugung der alzheimerschen erkrankungInfo
- Publication number
- ATE425750T1 ATE425750T1 AT01930965T AT01930965T ATE425750T1 AT E425750 T1 ATE425750 T1 AT E425750T1 AT 01930965 T AT01930965 T AT 01930965T AT 01930965 T AT01930965 T AT 01930965T AT E425750 T1 ATE425750 T1 AT E425750T1
- Authority
- AT
- Austria
- Prior art keywords
- alzheimer
- disease
- prevention
- treatment
- medium chain
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/25—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20098000P | 2000-05-01 | 2000-05-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE425750T1 true ATE425750T1 (de) | 2009-04-15 |
Family
ID=22743976
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT01930965T ATE425750T1 (de) | 2000-05-01 | 2001-05-01 | Verwendung von triglyceriden mit mittellangen ketten zur behandlung und vorbeugung der alzheimerschen erkrankung |
Country Status (10)
Country | Link |
---|---|
US (3) | US20020006959A1 (de) |
EP (3) | EP2319508A1 (de) |
JP (2) | JP2003531857A (de) |
AT (1) | ATE425750T1 (de) |
AU (1) | AU2001257451A1 (de) |
DE (1) | DE60138019D1 (de) |
DK (1) | DK1292294T3 (de) |
ES (2) | ES2752800T3 (de) |
PT (1) | PT1292294E (de) |
WO (1) | WO2001082928A1 (de) |
Families Citing this family (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6323237B1 (en) | 1997-03-17 | 2001-11-27 | Btg International Limited | Therapeutic compositions |
US6835750B1 (en) | 2000-05-01 | 2004-12-28 | Accera, Inc. | Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II |
US20080009467A1 (en) * | 2000-05-01 | 2008-01-10 | Accera, Inc. | Combinations of medium chain triglycerides and therapeutic agents for the treatment and prevention of alzheimers disease and other diseases resulting from reduced neuronal metabolism |
US20070179197A1 (en) * | 2000-05-01 | 2007-08-02 | Accera, Inc. | Compositions and methods for improving or preserving brain function |
EP2319508A1 (de) | 2000-05-01 | 2011-05-11 | Accera, Inc. | Verwendung von Triglyceriden von mittlerer Kettenlänge zur Behandlung und Vorbeugung vonAlzheimer und anderen Krankheiten resultierend aus verringertem neuronalem Metabolismus |
EP1605950A4 (de) * | 2003-03-06 | 2008-01-09 | Accera Inc | Neue chemische stoffe und verfahren zu ihrer verwendung bei der behandlung von stoffwechselstörungen |
GB0306394D0 (en) | 2003-03-20 | 2003-04-23 | Univ Nottingham | Carnitine retention |
WO2004108740A2 (en) | 2003-06-03 | 2004-12-16 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Nutritional supplements and therapeutic compositions comprising (r)-3-hydroxybutyrate derivatives |
GB0420856D0 (en) * | 2004-09-20 | 2004-10-20 | Ketocytonyx Inc | Cns modulators |
WO2006020179A2 (en) | 2004-07-20 | 2006-02-23 | Ketocytonyx Inc. | Oligomeric ketone compounds |
ES2574557T3 (es) * | 2004-09-21 | 2016-06-20 | Btg International Limited | Miméticos dopaminérgicos |
US7702343B2 (en) * | 2005-04-04 | 2010-04-20 | Qualcomm Incorporated | Efficient gap allocation for cell measurements in asynchronous communication networks |
US20060252775A1 (en) * | 2005-05-03 | 2006-11-09 | Henderson Samuel T | Methods for reducing levels of disease associated proteins |
FR2885491B1 (fr) * | 2005-05-16 | 2020-03-06 | Nutricos Technologies | Traitement de la secheresse keratinique par des glycerides |
EP1915144A4 (de) * | 2005-06-20 | 2009-08-19 | Accera Inc | Verfahren zur reduzierung von oxidativen schäden und zur verbesserung der mitochondrien-effizienz |
MX2008005936A (es) * | 2005-11-07 | 2008-10-01 | Perque Llc | Composiciones para regular trastornos metabolicos y metodos de uso de las mismas. |
EP1988971B1 (de) * | 2005-12-15 | 2018-02-28 | Nestec S.A. | Zusammensetzungen und verfahren zur erhaltung der gehirnfunktion |
LT2500017T (lt) * | 2006-04-03 | 2017-12-11 | Accera, Inc. | Ketogeninių junginių panaudojimas senatvinio atminties susilpnėjimo gydymui |
EP1929995A1 (de) | 2006-12-04 | 2008-06-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anaplerotische Therapie der Huntington-Krankheit und anderer Polyglutamin-Erkrankungen |
EP2134351B1 (de) * | 2007-03-13 | 2016-04-27 | Nutrition 21, Inc. | Verfahren und zusammensetzungen zur verzögerten freisetzung von chrom |
US8697138B2 (en) | 2007-03-28 | 2014-04-15 | Aker Biomarine As | Methods of using krill oil to treat risk factors for cardiovascular, metabolic, and inflammatory disorders |
EP2144618B1 (de) | 2007-03-28 | 2013-05-15 | Aker Biomarine ASA | Biologisch wirksame krill-öl-zusammensetzungen |
US20110003767A1 (en) * | 2007-05-14 | 2011-01-06 | Neuera Pharmaceuticals, Inc. | Inhibitors of Acetyl-CoA Carboxylase for Treatment of Neuronal Hypometabolism |
WO2009002145A1 (en) | 2007-06-26 | 2008-12-31 | N.V. Nutricia | Lipid composition for improving function of brain functioning |
WO2009002146A1 (en) | 2007-06-26 | 2008-12-31 | N.V. Nutricia | Supporting activities of daily living |
WO2009082203A1 (en) | 2007-12-20 | 2009-07-02 | N.V. Nutricia | Liquid nucleotides/nucleosides-containing product |
AU2008269728B2 (en) | 2007-06-26 | 2013-10-31 | N.V. Nutricia | Improving memory in subjects with mini-mental state examination of 24-26 |
ES2556535T3 (es) * | 2007-07-31 | 2016-01-18 | Accera, Inc. | Uso de ensayo genómico y compuestos cetogénicos para tratamiento de una función cognitiva reducida |
TR201908522T4 (tr) | 2008-01-04 | 2019-07-22 | The Government Of The U S A As Represented By The Secretary Dept Of Health And Human Services | Kan lipidi düşürücü maddeler olarak keton gövdeleri ve keton gövde esterleri. |
AU2009266869B2 (en) | 2008-07-03 | 2016-07-07 | Cerecin Inc. | Monoglyceride of acetoacetate and derivatives for the treatment of neurological disorders |
US8105809B2 (en) * | 2008-07-03 | 2012-01-31 | Accera, Inc. | Enzymatic synthesis of acetoacetate esters and derivatives |
MX2011000652A (es) * | 2008-07-18 | 2011-06-16 | Dart Neuroscience Llc | Metodos y sistemas para evaluar agentes para la memoria. |
US8642654B2 (en) | 2009-04-16 | 2014-02-04 | Isis Innovation Limited | Hydroxybutyrate ester and medical use thereof |
US8372812B2 (en) | 2009-02-26 | 2013-02-12 | Aker Biomarine Asa | Phospholipid and protein tablets |
MX348036B (es) * | 2009-12-30 | 2017-05-24 | Baylor Res Institute | Terapia anaplerótica para la enfermedad de alzheimer y el cerebro envejecido. |
GB201002983D0 (en) | 2010-02-22 | 2010-04-07 | Tdeltas Ltd | Nutritinal composition |
US8846061B1 (en) | 2011-03-08 | 2014-09-30 | Mark S. Bezzek | Multivitamin-mineral regimens for longevity and wellness |
US8349376B1 (en) * | 2011-03-08 | 2013-01-08 | Bezzek Mark S | Anti-dementia regimen |
US8183227B1 (en) | 2011-07-07 | 2012-05-22 | Chemo S. A. France | Compositions, kits and methods for nutrition supplementation |
DK2751279T3 (da) | 2011-08-31 | 2017-11-20 | St Jude Children's Res Hospital | Fremgangsmåder og sammensætninger til påvisning af niveauet af lysosomal exocytose-aktivitet og fremgangsmåder til anvendelse |
US8168611B1 (en) | 2011-09-29 | 2012-05-01 | Chemo S.A. France | Compositions, kits and methods for nutrition supplementation |
GB201210699D0 (en) * | 2012-06-15 | 2012-08-01 | Vitaflo Ltd | Nutritional food |
ES2752030T3 (es) | 2012-11-05 | 2020-04-02 | Us Health | Cuerpos cetónicos para proteger los tejidos del daño por radiación ionizante |
WO2014093901A1 (en) | 2012-12-13 | 2014-06-19 | Baylor Research Institute At Dallas | Triheptanoin for the treatment of glucose transporter 1 deficiency |
GB201304467D0 (en) | 2013-03-12 | 2013-04-24 | Tdeltas Ltd | Compound for use in protecting skin |
AU2014230120B2 (en) | 2013-03-14 | 2018-06-21 | Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services | Process for producing (R)-3hydroxybutyl (R)-3hydroxybutyrate |
BR112015024186B1 (pt) | 2013-03-19 | 2023-05-09 | University Of South Florida | Composições e métodos para produção de cetose de elevação e manutenção |
AU2014203179C1 (en) | 2013-06-14 | 2017-05-04 | Aker Biomarine Antarctic As | Lipid extraction processes |
EP3689343A1 (de) | 2013-11-14 | 2020-08-05 | The University of Queensland | Neurodegenerative erkrankungen und verfahren zur behandlung und diagnose mit verwendung anaplerotischer verbindungen |
GB201400431D0 (en) | 2014-01-10 | 2014-02-26 | Aker Biomarine As | Phospholipid compositions and their preparation |
MX2016010409A (es) * | 2014-02-11 | 2016-11-30 | Pharnext | Combinacion de baclofeno, acamprosato y trigliceridos de cadena media para el tratamiento de trastornos neurologicos. |
US10668041B2 (en) | 2014-12-08 | 2020-06-02 | Societe Des Produits Nestle Sa | Compositions and methods comprising medium chain triglycerides for treatment of epilepsy |
LT3229790T (lt) | 2014-12-08 | 2019-12-10 | Nestle Sa | Kompozicijos, apimančios vidutinės grandinės trigliceridus, skirtos panaudoti epilepsijos gydyme |
KR102310765B1 (ko) | 2015-02-11 | 2021-10-12 | 에이커 바이오마린 앤탁틱 에이에스 | 지질 조성물 |
ES2937960T3 (es) | 2015-02-11 | 2023-04-03 | Aker Biomarine Antarctic As | Proceso de extracción de lípidos |
CA3004986A1 (en) * | 2015-12-04 | 2017-06-08 | Nestec S.A. | Medium chain triglyceride compositions |
JP2019500024A (ja) * | 2015-12-04 | 2019-01-10 | ネステク ソシエテ アノニム | 認知を改善するための方法 |
US10736861B2 (en) | 2016-03-11 | 2020-08-11 | Axcess Global Sciences, Llc | Mixed salt compositions for producing elevated and sustained ketosis |
US10973792B2 (en) | 2019-02-13 | 2021-04-13 | Axcess Global Sciences, Llc | Racemic beta-hydroxybutyrate mixed salt-acid compositions and methods of use |
US10973786B2 (en) | 2016-03-11 | 2021-04-13 | Axcess Global Sciences, Llc | R-beta-hydroxybutyrate, S-beta-hydroxybutyrate, and RS-beta-hydroxybutyrate mixed salt compositions |
US10245243B1 (en) | 2017-12-19 | 2019-04-02 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use |
US10596130B2 (en) | 2017-12-19 | 2020-03-24 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use |
US10245242B1 (en) | 2017-11-22 | 2019-04-02 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
US11103470B2 (en) | 2017-11-22 | 2021-08-31 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
US11241403B2 (en) | 2016-03-11 | 2022-02-08 | Axcess Global Sciences, Llc | Beta-hydroxybutyrate mixed salt compositions and methods of use |
US10596131B2 (en) | 2017-11-22 | 2020-03-24 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
US10292952B2 (en) | 2016-03-11 | 2019-05-21 | Axcess Global Sciences, Llc | Mixed salt compositions for maintaining or restoring electrolyte balance while producing elevated and sustained ketosis |
US10596129B2 (en) | 2017-11-22 | 2020-03-24 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
US11185518B2 (en) | 2017-12-19 | 2021-11-30 | Axcess Global Sciences, Llc | S-beta-hydroxybutyrate compounds and compositions enriched with S-enantiomer |
US10736548B2 (en) * | 2016-05-18 | 2020-08-11 | Invoy Holdings, Inc. | Ketone measurement system for monitoring medical conditions |
WO2017211274A1 (en) | 2016-06-08 | 2017-12-14 | Dong Yuhong | Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement |
JP7246843B2 (ja) * | 2016-08-26 | 2023-03-28 | 日油株式会社 | スポーツ飲料 |
KR102306138B1 (ko) | 2017-03-15 | 2021-09-28 | 세레신 인코포레이티드 | 고 약물 부하량의 중쇄 트리글리세라이드를 갖는 약학 조성물 및 이와 관련된 방법 |
US11202769B2 (en) | 2017-11-22 | 2021-12-21 | Axcess Global Sciences, Llc | Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function |
US12090129B2 (en) | 2017-11-22 | 2024-09-17 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
US10925843B2 (en) | 2018-04-18 | 2021-02-23 | Axcess Global Sciences, Llc | Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate |
US11944598B2 (en) | 2017-12-19 | 2024-04-02 | Axcess Global Sciences, Llc | Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer |
US20210186915A1 (en) * | 2018-03-15 | 2021-06-24 | Cerecin Inc. | Pharmaceutical compositions having high drug loadings of medium chain triglycerides and methods related thereto |
US11419836B2 (en) | 2019-02-13 | 2022-08-23 | Axcess Global Sciences, Llc | Racemic and near racemic beta-hydroxybutyrate mixed salt-acid compositions |
US10980772B2 (en) | 2018-08-27 | 2021-04-20 | Axcess Global Sciences, Llc | Compositions and methods for delivering tetrahydrocannabinol and ketone bodies |
US11241401B2 (en) | 2020-02-06 | 2022-02-08 | Axcess Global Sciences, Llc | Enantiomerically pure r-beta-hydroxybutyrate mixed salt-acid compositions |
US11129802B2 (en) | 2018-08-27 | 2021-09-28 | Axcess Global Sciences, Llc | Compositions and methods for delivering cannabidiol and ketone bodies |
US11806324B2 (en) | 2018-04-18 | 2023-11-07 | Axcess Global Sciences, Llc | Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies |
US10512615B1 (en) | 2018-08-27 | 2019-12-24 | Axcess Global Sciences, Llc | Compositions and methods for delivering cannabidiol and ketone bodies |
US11033553B2 (en) | 2019-06-21 | 2021-06-15 | Axcess Global Sciences, Llc | Non-vasoconstricting energy-promoting compositions containing ketone bodies |
US11950616B2 (en) | 2019-06-21 | 2024-04-09 | Axcess Global Sciences, Llc | Non-vasoconstricting energy-promoting compositions containing ketone bodies |
US20230372276A1 (en) * | 2020-10-09 | 2023-11-23 | Cerecin Inc. | Methods for delivering medium chain triglycerides with controlled pharmacokinetic, safety and tolerability profiles |
US11969430B1 (en) | 2023-03-10 | 2024-04-30 | Axcess Global Sciences, Llc | Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance |
Family Cites Families (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2766145A (en) * | 1954-07-26 | 1956-10-09 | Reynolds Tobacco Co R | Tobacco |
US2766146A (en) * | 1954-07-26 | 1956-10-09 | Reynolds Tobacco Co R | Tobacco |
US3053677A (en) * | 1959-11-12 | 1962-09-11 | Eastman Kodak Co | Petroleum wax for paper coatings |
US4346107A (en) * | 1979-02-12 | 1982-08-24 | Claudio Cavazza | Pharmaceutical composition comprising acyl-carnitine for the treatment of impaired cerebral metabolism |
FR2490631A1 (fr) * | 1980-09-24 | 1982-03-26 | Roussel Uclaf | Nouvelle composition lipidique utilisable en dietetique, reanimation et therapeutique |
US4528197A (en) | 1983-01-26 | 1985-07-09 | Kabivitrum Ab | Controlled triglyceride nutrition for hypercatabolic mammals |
US4551523A (en) * | 1983-04-14 | 1985-11-05 | Eastman Kodak Company | Preparation of saccharide acetoacetates |
US4847296A (en) | 1984-09-13 | 1989-07-11 | Babayan Vigen K | Triglyceride preparations for the prevention of catabolism |
US5126373A (en) | 1987-11-19 | 1992-06-30 | Henri Brunengraber | Composition for parenteral and oral nutrition |
SE8803141L (sv) | 1988-09-07 | 1990-03-08 | Kabivitrum Ab | Naeringsmedel foer maenniskor och djur |
US5650148A (en) | 1988-12-15 | 1997-07-22 | The Regents Of The University Of California | Method of grafting genetically modified cells to treat defects, disease or damage of the central nervous system |
DE3843238C1 (de) * | 1988-12-22 | 1990-02-22 | Lohmann Therapie Syst Lts | |
IT1240775B (it) | 1990-02-23 | 1993-12-17 | Sigma Tau Ind Farmaceuti | Esteri della l-carnitina e di acil-l-carnitine con l'acido beta-idrossibutirrico e composizioni farmaceutiche che li contengono per la inibizione della degenerazione neuronale, della proteolisi epatica e nel trattamento del coma. |
ATE119746T1 (de) | 1990-04-26 | 1995-04-15 | Procter & Gamble | Polyol-fettsäure-polyester enthaltende backfettzusammensetzungen. |
US5385915A (en) | 1990-05-16 | 1995-01-31 | The Rockefeller University | Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation |
US5538983A (en) | 1990-05-16 | 1996-07-23 | The Rockefeller University | Method of treating amyloidosis by modulation of calcium |
US5614560A (en) * | 1991-04-04 | 1997-03-25 | Children's Medical Center Corporation | Method of preventing NMDA receptor-mediated neuronal damage |
GB9113484D0 (en) | 1991-06-21 | 1991-08-07 | Unilever Plc | Cosmetic composition |
US5276059A (en) * | 1992-07-10 | 1994-01-04 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibition of diseases associated with amyloid formation |
US5308832A (en) | 1992-07-27 | 1994-05-03 | Abbott Laboratories | Nutritional product for persons having a neurological injury |
EP0625212B1 (de) * | 1992-10-13 | 2004-03-24 | Duke University | VERFAHREN ZUM nachweis der Alzheimer Krankheit |
JP3486778B2 (ja) * | 1993-04-02 | 2004-01-13 | 三菱ウェルファーマ株式会社 | アルツハイマー病予防治療剤 |
US5420335A (en) | 1993-09-30 | 1995-05-30 | Birkhahn; Ronald H. | Parenteral nutrients based on watersoluble glycerol bisacetoacetates |
US5438042B1 (en) * | 1993-10-08 | 1997-08-26 | Sandoz Nutrition Ltd | Enteral nutritional composition having amino acid profile |
JP3645580B2 (ja) | 1993-10-22 | 2005-05-11 | 株式会社フジモト・ブラザーズ | グルコースエステル誘導体を含有する脳代謝改善剤 |
US5691325A (en) | 1994-01-14 | 1997-11-25 | Sandyk; Reuven | Method for ameliorating age-related disease conditions |
GB9408465D0 (en) * | 1994-04-27 | 1994-06-22 | Univ Mcgill | Apolipoprotein e polymorphism & treatment of alzheimer's disease |
US7049078B2 (en) * | 1994-04-27 | 2006-05-23 | Judés Poirier | Apolipoprotein E polymorphism and treatment of alzheimer's disease |
US5607967A (en) | 1994-10-27 | 1997-03-04 | Merck & Co., Inc. | Treatment of alzheimer's disease with 5-(tetradecyloxy)-2-furan carboxylic acid |
WO1996014063A1 (en) | 1994-11-08 | 1996-05-17 | Avicena Group, Inc. | Use of creatine or creatine analogs for the treatment of diseases of the nervous system |
US5854215A (en) | 1995-03-14 | 1998-12-29 | Praecis Pharmaceuticals Incorporated | Modulators of β-amyloid peptide aggregation |
US5854204A (en) | 1995-03-14 | 1998-12-29 | Praecis Pharmaceuticals, Inc. | Aβ peptides that modulate β-amyloid aggregation |
US5817626A (en) | 1995-03-14 | 1998-10-06 | Praecis Pharmaceuticals Incorporated | Modulators of beta-amyloid peptide aggregation |
US6022683A (en) * | 1996-12-16 | 2000-02-08 | Nova Molecular Inc. | Methods for assessing the prognosis of a patient with a neurodegenerative disease |
JP4598203B2 (ja) * | 1995-12-01 | 2010-12-15 | ビーティージー・インターナショナル・リミテッド | 脳機能改善剤 |
US5936078A (en) | 1995-12-12 | 1999-08-10 | Kyowa Hakko Kogyo Co., Ltd. | DNA and protein for the diagnosis and treatment of Alzheimer's disease |
DE19609476A1 (de) * | 1996-03-11 | 1997-09-18 | Basf Ag | Stabile zur parenteralen Verabreichung geeignete Carotinoid-Emulsionen |
IT1284650B1 (it) | 1996-05-24 | 1998-05-21 | Sigma Tau Ind Farmaceuti | Farmaco a base di un derivato della carnitina per il trattamento della demenza di alzheimer in pazienti ad insorgenza precoce della patologia |
KR980008239A (ko) * | 1996-07-26 | 1998-04-30 | 김충환 | 사이클로스포린-함유 약학적 조성물 |
EP1006794B1 (de) * | 1997-03-12 | 2007-11-28 | Robert W. Esmond | Verfahren zur behandlung oder prävention der alzheimerischen krankheit |
AU6513298A (en) * | 1997-03-17 | 1998-10-12 | British Technology Group Limited | Therapeutic compositions |
US6323237B1 (en) * | 1997-03-17 | 2001-11-27 | Btg International Limited | Therapeutic compositions |
US6316038B1 (en) * | 1997-03-17 | 2001-11-13 | Btg International Limited | Therapeutic compositions |
US6352722B1 (en) | 1997-12-23 | 2002-03-05 | Quadrant Holdings Cambridge Limited | Derivatized carbohydrates, compositions comprised thereof and methods of use thereof |
US20040058873A1 (en) * | 1998-03-12 | 2004-03-25 | Esmond Robert W. | Method for treating or preventing Alzheimer's disease |
WO1999051097A1 (en) | 1998-04-02 | 1999-10-14 | Avicena Group, Inc. | Compositions containing a combination of a creatine compound and a second agent |
DE69922206T2 (de) | 1998-07-22 | 2005-11-24 | Metabolix, Inc., Cambridge | Nahrungs- und therapeutische verwendung von hydroxyalkanoat oligomere |
AU6039199A (en) * | 1998-09-14 | 2000-04-03 | Pan Pacific Pharmaceuticals, Inc. | Useful properties of a bee venom protein and gene encoding same |
CN1273129C (zh) * | 1998-09-15 | 2006-09-06 | 英国技术集团国际有限公司 | 治疗组合物(ⅱ) |
GB9908202D0 (en) | 1999-04-12 | 1999-06-02 | Unilever Plc | Cosmetic compositions |
US20070179197A1 (en) * | 2000-05-01 | 2007-08-02 | Accera, Inc. | Compositions and methods for improving or preserving brain function |
EP2319508A1 (de) | 2000-05-01 | 2011-05-11 | Accera, Inc. | Verwendung von Triglyceriden von mittlerer Kettenlänge zur Behandlung und Vorbeugung vonAlzheimer und anderen Krankheiten resultierend aus verringertem neuronalem Metabolismus |
US6835750B1 (en) * | 2000-05-01 | 2004-12-28 | Accera, Inc. | Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II |
DE20012857U1 (de) * | 2000-07-27 | 2000-11-09 | Sportmedizin Team Vertriebs Gmbh, Berneck | Diätetisches Lebensmittel zum Fettabbau |
US6667397B2 (en) | 2000-08-25 | 2003-12-23 | Eastman Chemical Company | Methods of preparing disaccharide and trisaccharide C6-C12 fatty acid esters with high alpha content and materials therefrom |
GB2368011A (en) | 2000-10-17 | 2002-04-24 | Unilever Plc | Fatty acid esters of maltose and uses thereof |
US20020103139A1 (en) * | 2000-12-01 | 2002-08-01 | M. Weisspapir | Solid self-emulsifying controlled release drug delivery system composition for enhanced delivery of water insoluble phytosterols and other hydrophobic natural compounds for body weight and cholestrol level control |
CN1229107C (zh) | 2000-12-30 | 2005-11-30 | Lg生活健康株式会社 | 含有酰基取代的葡萄糖或蔗糖衍生物的皮肤美白化妆品 |
US7087649B2 (en) * | 2001-06-07 | 2006-08-08 | Eisai Co., Ltd. | Methods for preventing and treating diseases and conditions associated with cellular stress |
WO2003028631A2 (en) * | 2001-09-21 | 2003-04-10 | Accera, Inc. | Drug targets for alzheimer's disease and other diseases associated with decreased neuronal metabolism |
WO2004021980A2 (en) * | 2002-09-09 | 2004-03-18 | Mitochroma Research, Inc. | Compositions and methods for treating niddm and other conditions and disorders associated with ampk regulation |
US6884454B2 (en) | 2002-10-21 | 2005-04-26 | Julio Lionel Pimentel | Appetite suppressing diet bar |
US20050031651A1 (en) * | 2002-12-24 | 2005-02-10 | Francine Gervais | Therapeutic formulations for the treatment of beta-amyloid related diseases |
EP1605950A4 (de) | 2003-03-06 | 2008-01-09 | Accera Inc | Neue chemische stoffe und verfahren zu ihrer verwendung bei der behandlung von stoffwechselstörungen |
WO2004108740A2 (en) | 2003-06-03 | 2004-12-16 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Nutritional supplements and therapeutic compositions comprising (r)-3-hydroxybutyrate derivatives |
US20050013884A1 (en) * | 2003-07-16 | 2005-01-20 | Rennels M. Scott | Compositions and methods for treating heart disease |
US7148192B2 (en) | 2004-01-29 | 2006-12-12 | Ebwe Pharma Ges. M.H. Nfg.Kg | Neuroprotective dietary supplement |
US20060252775A1 (en) | 2005-05-03 | 2006-11-09 | Henderson Samuel T | Methods for reducing levels of disease associated proteins |
US8227408B2 (en) | 2005-09-07 | 2012-07-24 | Neurotez, Inc. | Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology |
EP1988971B1 (de) | 2005-12-15 | 2018-02-28 | Nestec S.A. | Zusammensetzungen und verfahren zur erhaltung der gehirnfunktion |
LT2500017T (lt) * | 2006-04-03 | 2017-12-11 | Accera, Inc. | Ketogeninių junginių panaudojimas senatvinio atminties susilpnėjimo gydymui |
WO2008005818A1 (en) | 2006-06-30 | 2008-01-10 | Stepan Co | Glyceride esters for the treatment of diseases associated with reduced neuronal metabolism of glucose |
-
2001
- 2001-05-01 EP EP10181854A patent/EP2319508A1/de not_active Withdrawn
- 2001-05-01 PT PT01930965T patent/PT1292294E/pt unknown
- 2001-05-01 US US09/845,741 patent/US20020006959A1/en not_active Abandoned
- 2001-05-01 EP EP09001380.6A patent/EP2065041B1/de not_active Expired - Lifetime
- 2001-05-01 AT AT01930965T patent/ATE425750T1/de active
- 2001-05-01 AU AU2001257451A patent/AU2001257451A1/en not_active Abandoned
- 2001-05-01 ES ES09001380T patent/ES2752800T3/es not_active Expired - Lifetime
- 2001-05-01 EP EP01930965A patent/EP1292294B1/de not_active Expired - Lifetime
- 2001-05-01 WO PCT/US2001/013955 patent/WO2001082928A1/en active Application Filing
- 2001-05-01 ES ES01930965T patent/ES2323940T3/es not_active Expired - Lifetime
- 2001-05-01 DK DK01930965T patent/DK1292294T3/da active
- 2001-05-01 DE DE60138019T patent/DE60138019D1/de not_active Expired - Lifetime
- 2001-05-01 JP JP2001579803A patent/JP2003531857A/ja active Pending
-
2006
- 2006-01-13 US US11/331,673 patent/US20060122270A1/en not_active Abandoned
-
2012
- 2012-04-12 US US13/445,679 patent/US8426468B2/en not_active Expired - Lifetime
- 2012-05-07 JP JP2012105692A patent/JP5701245B2/ja not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
US20120196932A1 (en) | 2012-08-02 |
DK1292294T3 (da) | 2009-06-22 |
EP1292294A4 (de) | 2004-04-14 |
JP2012188431A (ja) | 2012-10-04 |
WO2001082928A9 (en) | 2006-06-15 |
ES2752800T3 (es) | 2020-04-06 |
JP2003531857A (ja) | 2003-10-28 |
PT1292294E (pt) | 2009-06-01 |
US8426468B2 (en) | 2013-04-23 |
US20020006959A1 (en) | 2002-01-17 |
EP2065041B1 (de) | 2019-07-31 |
AU2001257451A1 (en) | 2001-11-12 |
EP2319508A1 (de) | 2011-05-11 |
JP5701245B2 (ja) | 2015-04-15 |
ES2323940T3 (es) | 2009-07-28 |
EP1292294B1 (de) | 2009-03-18 |
EP2065041A1 (de) | 2009-06-03 |
AU2001257451A8 (en) | 2006-11-09 |
EP1292294A1 (de) | 2003-03-19 |
DE60138019D1 (de) | 2009-04-30 |
WO2001082928A1 (en) | 2001-11-08 |
US20060122270A1 (en) | 2006-06-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE425750T1 (de) | Verwendung von triglyceriden mit mittellangen ketten zur behandlung und vorbeugung der alzheimerschen erkrankung | |
DK0721449T3 (da) | Inhibitorer af beta-amyloidproteinproduktion | |
ATE385794T1 (de) | Benzothiazolderivate zur behandlung von alzheimer und parkinson | |
ATE427114T1 (de) | Verwendung von hepcidin zur herstellung eines arzneimittels zur behandlung von eisenhomíostase stírungen | |
ATE374029T1 (de) | Behandlung der alzheimer-krankheit durch erhöhung des cytidin-spiegels in vivo | |
ATE202940T1 (de) | Mittel und methoden zur behandlung von plaque- krankheiten | |
DE69620306D1 (de) | 4-(.Alpha.-hydroxy-.alpha.-aryl-alkylcarbonylamino)-Piperidine zur Behandlung und Prophylaxe von Erkrankungen der Harnwege | |
ATE178487T1 (de) | Verwendung von 2-amino-4-(4-fluorbenzylamino)-1- ethoxycarbonylaminobenzen zur prophylaxe und behandlung der folgen der akuten und chronischen zerebralen minderdurchblutung sowie neurodegenerativer erkrankungen | |
ATE396174T1 (de) | Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten | |
DE60027913D1 (de) | 5-beta-sapogenin und pseudosapogeninderivate und ihre verwendung zur behandlung von demenz | |
DE60237635D1 (de) | Verwendung von pramipexol zur behandlung von amyotrophischer lateralsklerose | |
DE69519577D1 (de) | Prednisolonmetasulfobenzoatzusammensetzung zur behandlung von entzündungserkrankung des darmes | |
ATE526981T1 (de) | Verwendung von vegf 165 und homologen zur behandlung von neurologischen störungen | |
ATE212548T1 (de) | Behandlung und prophylaxe von pankreatitis | |
NO20051664L (no) | Behandling av demens og Parkinsons sykdom | |
ATE217191T1 (de) | Verwendung von phanquinon zur behandlung von alzheimer's krankheit | |
ATE269705T1 (de) | Verwendung von optisch reinem (r)-tofizopam zur behandlung und pravention von angststörungen | |
ATE294584T1 (de) | Verwendung von desoxypeganin zur behandlung von alzheimerischer demenz | |
DE69913380D1 (de) | Zusammensetzung zur behandlung von periodontalen erkrankungen | |
ATE314064T1 (de) | L-acetylcarnitin und l-propionylcarnitin zusammensetzung zur verhütung und behandlung von nierenstörungen und nierenenkrankheit | |
DE69710526D1 (de) | Verwendung von 3-(4-Hexyloxy-1,2,5-Thiadiazol-3-yl)-1,2,5,6-Tetrahydro-1-Methylpyridin (Xanomelin) zur Behandlung von bipolaren Störungen | |
DE60107516D1 (de) | Verwendung von Pregabalin zur Asthma Behandlung | |
DE69827706D1 (de) | 5-(Heteroaryl)alkyl)-3-oxo-pyrido(1,2-a)benzimidazol-4-carboxamid (PBI) Derivate zur Behandlung von Störungen des zentralen Nervensystems | |
DE69808607D1 (de) | Verfahren zur verwendung von cyclooxygenase-2 hemmern zur behandlung und vorbeugung der demenz | |
ATE224711T1 (de) | Formulierung zur behandlung und/oder vorbeugung von dementia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1292294 Country of ref document: EP |